Results 101 to 110 of about 22,259 (250)

Hepatocarcinoma sobre hígado ectópico peritoneal [PDF]

open access: yes, 2019
El hepatocarcinoma (HCC) sobre hígado ectópico es una entidad rara. La mayoría de los casos son asintomáticos y se descubren de manera casual en una autopsia o laparoscopia.
Martinez-Acitores de la Mata, D..   +9 more
core   +1 more source

Metabolic mRNA insufficiency of single cells: Implications for drug targeting and resistance

open access: yesThe FEBS Journal, EarlyView.
Because none of the single‐cell mRNA profiles of growing cell populations encoded any pathway towards cell growth, we used cluster‐averaged transcriptomes to estimate protein‐constrained Vmax's and identify (combinations of) subpopulation‐specific targets to overcome drug resistance. (Graphical Abstract was created in BioRender. Liu, Y. (2026). https://
Yanhua Liu, Hans V. Westerhoff
wiley   +1 more source

Bioactivity-guided isolation of antioxidant and anti-hepatocarcinoma constituents from Veronica ciliata

open access: yes, 2016
Background: Veronica ciliata Fisch., widely distributed in western China, has been traditionally used in Tibetan Medicine as a treatment for hepatitis, cholecystitis, rheumatism, and urticaria. However, V. ciliata Fisch.
Lu, QX   +7 more
core   +1 more source

The Oral‐Hepatic Axis: Epidemiological and Mechanistic Links Between Periodontal and Liver Diseases

open access: yesJournal of Periodontal Research, EarlyView.
This review summarizes current epidemiological, clinical and mechanistic evidence linking periodontitis and chronic liver diseases, highlighting the oral‐gut‐liver axis, shared immunometabolic and nutritional pathways and opportunities for integrated preventive and therapeutic strategies.
Sinem Esra Sahingur   +3 more
wiley   +1 more source

Periodontitis and metabolic dysfunction‐associated steatotic liver disease

open access: yesPeriodontology 2000, EarlyView.
Abstract Objective Periodontitis is a chronic inflammatory disease with systemic effects that extend beyond the oral cavity and contribute to systemic immune and metabolic dysregulation. Chronic liver diseases, particularly metabolic dysfunction‐associated steatotic liver disease (MASLD) and its progressive phenotypes, have emerged as major global ...
Rafael Scaf de Molon   +6 more
wiley   +1 more source

The Higher Incidence of Liver Injury in HCC Patients Compared to Other Malignancies During Immune-Checkpoint Inhibitor Therapy is Primarily Due to Tumor Progression

open access: yesTherapeutics and Clinical Risk Management
Yan Wang,1,* Liwei Liu,2,* Mengyu Zhao,1,* Wei Chen,3 Yu Chen,2 Xinyan Zhao1 1Liver Research Center, Beijing Friendship Hospital, Key Laboratory on Translational Medicine on Cirrhosis, National Clinical Research Center for ...
Wang Y   +5 more
doaj  

Combined hepatocarcinoma-cholangiocarcinoma in patients treated as hepatocarcinoma [PDF]

open access: yesHPB, 2018
L.A. Martinez Insfran   +9 more
openaire   +1 more source

Hepatocarcinoma. Hemoperitoneo

open access: yesCirugía del Uruguay, 1974
Presentamos un caso de carcinoma primitivo de higado, en el cual destacamos: la forma de presentación clínica, la aparición de un hígado no cirrótico, la presencia de un hemoperitoneo, y la aparición multicéntrica del tumor.
Juan Chifflet   +2 more
openaire   +1 more source

Quimioembolización hepática en el manejo terapéutico del hepatocarcinoma: reporte de dos casos

open access: yes, 2017
Chemoembolization is a therapeutic alternative for those patients with hepatocarcinoma that cannot be excised surgically or that are waiting a liver allograft. We report two patients with hepatocarcinoma who were subjected to chemoembolization.
Meneses, Luis   +3 more
core  

The distinct roles of mesenchymal stem cells in the initial and progressive stage of hepatocarcinoma

open access: yes, 2018
Increasing evidences suggest that mesenchymal stem cells (MSCs) could migrate to the tumor site and play a vital role in tumorigenesis and progression. However, it is still a lively debate whether MSCs exert a pro- or anticancer action.
Fei Ye   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy